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Study Short Form–12 (SF–12) and the Arizona Sexual Experi-
ence Scale (ASEX) were also administered to measure health
status and current sexual functioning, respectively. From the
survey data, a set of four preliminary estimates of ADSD preva-
lence was developed for each country. RESULTS: Use of the most
liberal estimation algorithm resulted in 32.8% of the French
patients and 52% of the UK patients being classiﬁed as suffer-
ing from ADSD; 20.4% of the French sample and 21.6% of the
UK sample were categorized as having ADSD using the most
conservative algorithm. The study results also suggested that
ADSD negatively impacts patients’ quality of life. For example,
when patients were asked about the extent to which any changes
in their sexual functioning negatively affected their self-esteem
and relationships with sexual partners, signiﬁcant differences
were found between ADSD and non-ADSD subjects using all
four prevalence estimate deﬁnitions. CONCLUSION: The
results of this study suggest that both the prevalence and impact
of ADSD in Europe are substantial. A follow-up study with an
expanded scope is currently planned to further elucidate these
issues.
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OBJECTIVES: Pharmacological treatment with alpha1-blockers
is a method used to relieve benign prostatic hyperplasia (BPH)
symptoms. Non-selective alpha1-blockers, doxazosin (DOX) and
terazosin (TER), are currently available in generic and branded
forms; the selective alpha1A-blocker, tamsulosin (TAMS), is avail-
able branded only. This study compares total health care costs
(medical and pharmacy) for patients taking TAMS compared to
those receiving DOX or TER. METHODS: A retrospective
claims analysis was performed using a large national health
plan’s database for 1999–2001. Study population consisted of
males, 40 years or older, with an initial pharmacy claim date
(index date) for TAMS, DOX or TER during the identiﬁcation
period (2000). Cohorts were formed by drug received at index
date; generic and branded products were included. Propensity
score matching was used to balance cohort baseline characteris-
tics, for TAMS versus DOX (N = 1430) and TAMS versus TER
(N = 588) in separate intent-to-treat analyses. Health care costs
between cohorts for 12 months post-index date were collected
and compared as logarithmic average costs using multivariate
regression. RESULTS: In each analysis, propensity score match-
ing was successful in eliminating baseline population differences
for 28 variables related to demographics, comorbidities, health
care visits and costs except for 2 of 7 geographic region vari-
ables. The DOX analysis found no statistically signiﬁcant dif-
ferences in total costs or BPH-medical costs for TAMS ($5936
and $361) versus DOX ($5915 and $472), although pharmacy
costs were statistically signiﬁcantly higher (p < 0.05) for TAMS
($1798) versus DOX ($1583). The TER analysis found no 
statistically signiﬁcant differences in total costs, BPH-medical
costs, or pharmacy costs for TAMS ($5946, $378, $1896) versus
TER ($6807, $791, $1683), respectively. CONCLUSIONS: This
study demonstrates the importance of considering total health
care costs instead of only pharmacy costs when comparing
alpha1-blocker treatment for BPH. Differences in total and
medical costs for TAMS offset potential pharmacy cost beneﬁts
from DOX or TER.
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